Payment overview · 2025
General Payments
$4,033.29
54 reported records · 21 companies
Healthcare provider profile · identity verified
Dharmesh Mehta, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MAYFIELD VILLAGE, OH · NPI 1629381363
Verified facts
What the public records show
CMS Open Payments records show Dharmesh Mehta, M.D. received $4,033.29 in general payments during 2025 across 54 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 75.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Xifaxan.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rytary by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 942 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 942 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $3,041.84 | 75.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $175.27 | 4.3% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $98.76 | 2.5% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $94.34 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.97 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.53 | 1.6% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.35 | 1.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.91 | 1.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.08 | 1.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.65 | 1.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.04 | 1.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.28 | 1.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.04 | 0.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $31.36 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.63 | 0.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.91 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.89 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.71 | 0.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.68 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.90 | 0.3% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $13.15 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,609.50 | 1 |
| Food and Beverage | $1,332.13 | 52 |
| Travel and Lodging | $91.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $3,041.84 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $133.96 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.47 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $98.76 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $94.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $83.88 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $61.68 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $57.35 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.04 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.04 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.28 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $31.36 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.34 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $13.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 942 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
942 | 104 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
149 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
942 | 104 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1503 | 326 |
| Eliquis | Apixaban | 942 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 715 | 161 |
| Gabapentin | Gabapentin | 669 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 586 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 490 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 128 |
| Metoprolol Tartrate | Metoprolol Tartrate | 432 | 94 |
| Lisinopril | Lisinopril | 419 | 102 |
| Furosemide | Furosemide | 417 | 105 |
| Carvedilol | Carvedilol | 391 | 71 |
| Potassium Chloride | Potassium Chloride | 391 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 371 | 78 |
| Omeprazole | Omeprazole | 360 | 105 |
| Losartan Potassium | Losartan Potassium | 338 | 86 |
| Metformin Hcl | Metformin Hcl | 306 | 82 |
| Trazodone Hcl | Trazodone Hcl | 301 | 67 |
| Baclofen | Baclofen | 280 | 62 |
| Allopurinol | Allopurinol | 272 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 263 | 46 |
| Sertraline Hcl | Sertraline Hcl | 253 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 219 | 55 |
| Levetiracetam | Levetiracetam | 197 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 194 | 46 |
| Donepezil Hcl | Donepezil Hcl | 191 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 190 | 56 |
| Mirtazapine | Mirtazapine | 189 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 56 |
| Famotidine | Famotidine | 186 | 39 |
| Divalproex Sodium | Divalproex Sodium | 161 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 46 |
| Buspirone Hcl | Buspirone Hcl | 153 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 152 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 151 | 42 |
| Spironolactone | Spironolactone | 151 | 40 |
| Torsemide | Torsemide | 150 | 35 |
| Xarelto | Rivaroxaban | 149 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 148 | 36 |
| Jardiance | Empagliflozin | 137 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 26 |
| Prednisone | Prednisone | 128 | 60 |
| Warfarin Sodium | Warfarin Sodium | 124 | 16 |
| Cephalexin | Cephalexin | 121 | 48 |
| Bupropion Xl | Bupropion Hcl | 104 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 16 |
| Olanzapine | Olanzapine | 97 | 16 |
| Ezetimibe | Ezetimibe | 93 | 22 |
| Aripiprazole | Aripiprazole | 92 | 12 |
| Simvastatin | Simvastatin | 91 | 26 |
| Sucralfate | Sucralfate | 90 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 88 | 19 |
| Januvia | Sitagliptin Phosphate | 85 | 17 |
| Memantine Hcl | Memantine Hcl | 85 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 13 |
| Alendronate Sodium | Alendronate Sodium | 83 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 28 |
| Farxiga | Dapagliflozin Propanediol | 81 | 15 |
| Finasteride | Finasteride | 77 | 21 |
| Brimonidine Tartrate | Brimonidine Tartrate | 75 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 36 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 74 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 71 | 19 |
| Midodrine Hcl | Midodrine Hcl | 71 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 16 |
| Azithromycin | Azithromycin | 64 | 41 |
| Latanoprost | Latanoprost | 64 | 20 |
| Trulicity | Dulaglutide | 64 | 16 |
| Atenolol | Atenolol | 63 | 14 |
| Glimepiride | Glimepiride | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 58 | 18 |
| Ozempic | Semaglutide | 58 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | suppressed |
| Risperidone | Risperidone | 56 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 24 |
| Pregabalin | Pregabalin | 51 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 51 | suppressed |
| Lidocaine | Lidocaine | 50 | 11 |
| Nifedipine Er | Nifedipine | 50 | 15 |
| Methocarbamol | Methocarbamol | 48 | 22 |
| Nystatin | Nystatin | 48 | 29 |
| Ceftriaxone | Ceftriaxone Sodium | 47 | 23 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Topiramate | Topiramate | 47 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 28 |
| Meloxicam | Meloxicam | 46 | 16 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 33 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | 12 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 17 |
| Tramadol Hcl | Tramadol Hcl | 41 | 24 |
| Linzess | Linaclotide | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 12 |
| Constulose | Lactulose | 39 | suppressed |
| Humalog | Insulin Lispro | 39 | 12 |
| Ibuprofen | Ibuprofen | 39 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 20 |
| Valsartan | Valsartan | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Glipizide | Glipizide | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Procrit | Epoetin Alfa | 35 | suppressed |
| Naproxen | Naproxen | 34 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Fanapt | Iloperidone | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 30 | 21 |
| Lorazepam | Lorazepam | 30 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 20 |
| Veltassa | Patiromer Calcium Sorbitex | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 17 |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Rytary | Carbidopa/Levodopa | 28 | suppressed |
| Colchicine | Colchicine | 27 | 12 |
| Lacosamide | Lacosamide | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 26 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Enulose | Lactulose | 26 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 19 |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 21 |
| Metronidazole | Metronidazole | 25 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | 13 |
| Insulin Lispro | Insulin Lispro | 23 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | 12 |
| Dantrolene Sodium | Dantrolene Sodium | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 21 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 20 | 11 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 20 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 19 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Clozapine | Clozapine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Acetic Acid | Acetic Acid | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Nyamyc | Nystatin | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Octreotide Acetate | Octreotide Acetate | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,033.29 · 54 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, BRILINTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, OFEV, OTEZLA, REPATHA, REXULTI, SPRAVATO, The Cologuard Plus Collection Kit, UNITHROID, VYNDAMAX, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error